<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="publisher-id">GRP</journal-id><journal-title-group><journal-title>Gastroenterology Research and Practice</journal-title></journal-title-group><issn pub-type="ppub">1687-6121</issn><issn pub-type="epub">1687-630X</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4346691</article-id><article-id pub-id-type="doi">10.1155/2015/896560</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9983-8641</contrib-id><name><surname>Murphy</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Ronan J.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Upper Aerodigestive Malignancies Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA</aff><aff id="I2"><sup>2</sup>Gastroesophageal Cancer Therapeutics Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G93, Baltimore, MD 21231, USA</aff><author-notes><corresp id="cor1">*Ronan J. Kelly: <email>rkelly25@jhmi.edu</email></corresp><fn fn-type="other"><p>Academic Editor: Antoni Castells</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>896560</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 A. Murphy and R. J. Kelly.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Histological classification of adenocarcinoma or squamous cell carcinoma for esophageal cancer or using the Lauren classification for intestinal and diffuse type gastric cancer has limited clinical utility in the management of advanced disease. Germline mutations in E-cadherin (<italic>CDH1</italic>) or mismatch repair genes (Lynch syndrome) were identified many years ago but given their rarity, the identification of these molecular alterations does not substantially impact treatment in the advanced setting. Recent molecular profiling studies of upper GI tumors have added to our knowledge of the underlying biology but have not led to an alternative classification system which can guide clinician's therapeutic decisions. Recently the Cancer Genome Atlas Research Network has proposed four subtypes of gastric cancer dividing tumors into those positive for Epstein-Barr virus, microsatellite unstable tumors, genomically stable tumors, and tumors with chromosomal instability. Unfortunately to date, many phase III clinical trials involving molecularly targeted agents have failed to meet their survival endpoints due to their use in unselected populations. Future clinical trials should utilize molecular profiling of individual tumors in order to determine the optimal use of targeted therapies in preselected patients.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>While the incidence of gastric cancer is decreasing in the United States, the rates of esophageal cancer are increasing. In 2014 it is anticipated that 22,220 and 18,170 patients will be newly diagnosed with gastric cancer and esophageal cancer, respectively, while 26,440 men and women will die as a result of upper gastrointestinal (GI) tumors [<xref rid="B1" ref-type="bibr">1</xref>]. Gastroesophageal cancer remains endemic in many parts of the world with an estimated new cancer incidence of 1,471,000 or 11.6% of the global cancer burden and a death rate annually of 1,144,000 people or 15.1% of cancer-related deaths worldwide. Taken together, esophageal cancer and gastric cancer are second only to lung cancer in incidence and in mortality [<xref rid="B2" ref-type="bibr">2</xref>]. Despite these figures, there has been a dearth of scientific breakthroughs in these tumor types which have resulted in significant survival advantages.</p><p>The location of upper GI tumors in western countries has changed dramatically in recent years. Distal gastric cancer, which previously predominated, has become uncommon, whereas the incidence of tumors of the gastric cardia and gastroesophageal junction has increased dramatically. Prior to the 1970s, distal esophageal adenocarcinomas were uncommon, representing 0.8&#x02013;3.7% of esophageal cancers [<xref rid="B3" ref-type="bibr">3</xref>]. Over the past three decades, there has been a sevenfold increase in the incidence of esophageal adenocarcinoma among US white males, now accounting for more than half of the cases of esophageal cancer. Through the 1980s, the increases in the rates of these tumors have been on the order of 5&#x02013;10% per year, a faster pace than for virtually any other cancer in the United States [<xref rid="B3" ref-type="bibr">3</xref>]. This has been attributed to declining chronic infection rates by<italic> Helicobacter pylori</italic> and an increased incidence of gastroesophageal reflux disease and obesity [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>].</p></sec><sec id="sec2"><title>2. Cytotoxic Chemotherapy for Gastroesophageal Cancer</title><p>The treatment of metastatic gastroesophageal junction and gastric cancer has been poorly investigated and at present there is no single chemotherapeutic regimen that is considered standard first-line treatment. Various combinations of platinum-based doublets and triplets have been prescribed depending on patient performance status and physician preference. Current therapy for advanced disease is limited and survival rarely exceeds one year despite aggressive treatment with modern chemotherapy. Second-line regimens have, until recently, been considered ineffective. A number of different drugs (e.g., alkylating agents, platinum compounds, 5&#x02009;FU, and taxanes) are available for the treatment of gastroesophageal cancer but no means of selecting therapy based upon the biology of the tumor is currently available (<xref ref-type="table" rid="tab1">Table 1</xref>). HER2 status remains the only validated molecular marker which influences clinician decision-making in the metastatic setting. At present the combination of a platinum and fluorouracil, either alone or in combination with a third drug such as epirubicin or a taxane, constitutes the most effective treatment option in the first-line metastatic setting [<xref rid="B7" ref-type="bibr">7</xref>]. Standard first-line options include DCF (docetaxel, cisplatin, and 5&#x02009;FU), ECF/EOX (epirubicin, cisplatin/oxaliplatin, and 5&#x02009;FU/capecitabine), or FOLFOX (5&#x02009;FU, oxaliplatin) [<xref rid="B8" ref-type="bibr">8</xref>&#x02013;<xref rid="B10" ref-type="bibr">10</xref>]. Additional FDA approved 2nd line agents include docetaxel, paclitaxel, and irinotecan [<xref rid="B11" ref-type="bibr">11</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>].</p></sec><sec id="sec3"><title>3. Molecular Classification of Gastric Cancer</title><p>Molecular profiling studies have been performed using gene expression or DNA sequencing and have identified distinctive molecular signatures which may predict responsiveness to systemic therapies. Earlier studies in gastric cancer concentrated on molecular signatures which characterized the processes of tumorigenesis. Microarray-based gene expression profiling identified characteristic expression patterns which readily discern premalignant from malignant tissues [<xref rid="B15" ref-type="bibr">15</xref>]. Chronic gastritis tissue expressed a marked mitochondrial gene expression signature possibly as a response to<italic> H. pylori</italic> infection, for example,<italic> NDUF</italic> (NADH dehydrogenase), whereas intestinal metaplastic tissue expressed a more transformed phenotype including many intestinal differentiation genes which were not expressed in tumor tissues, for example,<italic> CDX1</italic>,<italic> MYO1A</italic>, and<italic> villin A</italic>. Later studies examined whether the molecular signature could predict sensitivity to chemotherapy [<xref rid="B16" ref-type="bibr">16</xref>]. Genomic subtypes (intestinal and diffuse) identified from<italic> in vitro</italic> studies in gastric cancer and validated in primary tumors were found to be prognostic of survival and had the ability to predict sensitivity to 5&#x02009;FU and/or platinum agents. It was possible to detect these subtypes by immunohistochemical analysis of<italic> LGALS4</italic> and<italic> CDH17</italic> expression. These studies may ultimately identify predictive biomarkers allowing physicians to personalize chemotherapy selection in gastric cancer.</p><p>Molecular profiling has been extended in an attempt to predict responsiveness to targeted therapies [<xref rid="B17" ref-type="bibr">17</xref>]. Gene expression patterns were analyzed with advanced bioinformatics tools to identify molecular signature subtypes which predicted response to inhibitors of the PI3K/Akt/mTOR pathway.</p><p>The Cancer Genome Atlas Research Network (TCGA) has recently performed a comprehensive molecular characterization of gastric tumors from 295 patients who had not been treated with prior chemotherapy or radiotherapy [<xref rid="B18" ref-type="bibr">18</xref>]. Detailed genetic analysis was performed using array-based somatic copy number analysis, whole-exome sequencing, array-based DNA methylation profiling, mRNA sequencing, microRNA sequencing, and reverse-phase protein arrays. It has proposed four subtypes (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>): (1) tumors positive for Epstein-Barr virus, (2) microsatellite unstable tumors, (3) genomically stable tumors, and (4) tumors with chromosomal instability.</p><p>EBV-associated tumors were shown to have a higher prevalence of DNA hypermethylation than any other tumor reported by the TCGA. All EBV-positive tumors displayed<italic> CDKN2A</italic> promoter hypermethylation and 80% had<italic> PIK3CA</italic> mutations. In addition, PD-L1/2 expression was elevated in EBV-positive tumors suggesting a role of targeted immunotherapy in this subset of gastric tumors. Microsatellite unstable (MSI) tumors generally lacked targetable amplifications although mutations in<italic> PIK3CA</italic>,<italic> HER2</italic>,<italic> HER3</italic>, and<italic> EGFR</italic> were noted.<italic> BRAF</italic> (V600E) mutations were not seen in gastric MSI tumors unlike its counterpart in colorectal cancer. Genomically stable gastric tumors are enriched for the diffuse histological variant and have newly described mutations in<italic> RHOA</italic> which acts through several effectors to control actin-myosin-dependent cell contractility and motility. In addition, a recurrent interchromosomal translocation (between<italic> CLDN18</italic> and<italic> ARHGAP26</italic>) implicated in cell motility was found in genomically stable gastric tumors. Almost half of gastric tumors demonstrated chromosomal instability which was characterized by marked aneuploidy and focal amplification of receptor tyrosine kinases such as amplification of<italic> VEGFA</italic> and frequent amplifications of cell cycle mediators (<italic>CCNE1</italic>,<italic> CCND1</italic>, and<italic> CDK6</italic>). This study has considerably added to our knowledge of the molecular subtyping of gastric cancer and hopefully will permit improved patient selection for clinical trials in the future.</p></sec><sec id="sec4"><title>4. Molecular Classification of Esophageal Cancer</title><p>Chromosomal aberrations leading to gene dysregulation have been reported in esophageal cancer including amplifications on 8q and 17q mapped to the<italic> C-MYC</italic> and<italic> ERBB2</italic> oncogenes [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>].</p><p>The role of<italic> MYC</italic> in the pathogenesis of esophageal cancer is not well defined and additional research is required. Loss of heterozygosity of TP53 occurs in greater than 50% of cases of esophageal cancer and is considered a strong predictor of disease progression [<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>]. In addition, two genes reported to have homozygous deletions in esophageal cancer are<italic> p16/CDKN2A</italic> and<italic> FHIT</italic> [<xref rid="B24" ref-type="bibr">24</xref>]. Abeloff et al. performed an integrative analysis of array-comparative genomic hybridization and matched gene expression profiling to reveal novel genes with prognostic significance in esophageal adenocarcinomas [<xref rid="B25" ref-type="bibr">25</xref>]. The authors identified 17 common regions (&#x0003e;5%) of gain and 11 common regions of losses in 56 resected specimens with associated long-term clinical follow-up data. Novel regions identified included loci 11p13 and 21q21.2.</p><p>Genes with high copy number and expression correlations included two deletions (<italic>p16/CDKN2</italic>,<italic> MBNL1</italic>) and four gains (<italic>EGFR</italic>,<italic> WT1</italic>,<italic> NEIL2</italic>, and<italic> MTMR9</italic>). These genes individually (<italic>P</italic> &#x0003c; 0.06) and collectively had prognostic significance (<italic>P</italic> = 0.008). A host of additional genes have been studied for mutations in esophageal cancer, but in most of these single gene studies, very few mutations have been identified. In an effort to perform a comprehensive evaluation of all coding regions for mutations, Agrawal et al. performed a comprehensive study of esophageal cancer exomes including both adenocarcinomas and squamous cell carcinomas [<xref rid="B26" ref-type="bibr">26</xref>]. Inactivating mutations of<italic> NOTCH1</italic> were identified in 21% of esophageal squamous cell carcinomas but not in adenocarcinomas.</p><p>Dulak et al. conducted an analysis of somatic copy-number alterations using high-density genomic profiling arrays in 296 esophageal and gastric cancers [<xref rid="B27" ref-type="bibr">27</xref>]. Amplified genes were noted in 37% of gastric/esophageal tumors, including<italic> ERBB2</italic>,<italic> FGFR1</italic>,<italic> FGFR2</italic>,<italic> EGFR</italic>, and<italic> MET</italic>, suggesting that some of these may be viable targets in esophageal cancer although amplification of some of these may be more prevalent in gastric tumors.</p></sec><sec id="sec5"><title>5. Molecular Targets in Advanced Disease</title><sec id="sec5.1"><title>5.1. HER2</title><p>HER2 is a protooncogene which is encoded by<italic> ERBB2</italic> found on chromosome 17. It belongs to the HER family of membrane-bound receptor tyrosine kinases which is responsible for the initiation of cell signaling pathways via phosphoinositide 3-kinase, phospholipase C, and mitogen-activated protein kinase [<xref rid="B28" ref-type="bibr">28</xref>]. While originally known for its effects in breast cancer, HER2 overexpression has been shown to result in worse prognosis in gastric cancer [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>] although there are conflicting studies which suggest that it has no effect or is even beneficial in terms of prognosis [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>].</p><p>The TOGA trial was a phase III prospective trial which demonstrated the benefits of adding trastuzumab, a humanized monoclonal antibody targeting HER2, to a platinum-based doublet in the presence of HER2 IHC 2+ or FISH amplified metastatic gastroesophageal or gastric cancer [<xref rid="B33" ref-type="bibr">33</xref>]. In this trial, 594 patients were randomly assigned to study treatment (trastuzumab plus chemotherapy, <italic>n</italic> = 298; chemotherapy alone, <italic>n</italic> = 296), of whom 584 were included in the primary analysis (<italic>n</italic> = 294; <italic>n</italic> = 290). Median overall survival was 13.8 months (95% CI 12&#x02013;16 months) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months in those assigned to chemotherapy alone (hazard ratio 0.74; 95% CI 0.60&#x02013;0.91; <italic>P</italic> = 0.0046). Unfortunately only 15&#x02013;20% of patients with esophageal or gastroesophageal tumors are HER2 positive [<xref rid="B32" ref-type="bibr">32</xref>] and intestinal-type disease and tumors at the gastroesophageal junction and proximal stomach have higher HER2 expression [<xref rid="B33" ref-type="bibr">33</xref>]. The benefit of trastuzumab was confined to those with IHC 2+/3+ and FISH positivity.</p><p>The practice of maintenance trastuzumab and continuing trastuzumab until evidence of disease progression are commonplace in the management of breast cancer [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>] but there is a lack of data indicating that this is a successful strategy in gastroesophageal cancer although a Japanese trial is currently investigating this approach [<xref rid="B36" ref-type="bibr">36</xref>]. The development of resistance to trastuzumab has prompted investigating alternative drugs which target HER2. Lapatinib is an oral dual tyrosine kinase inhibitor which targets EGFR and HER2 domains resulting in blocked autophosphorylation and downstream signaling [<xref rid="B37" ref-type="bibr">37</xref>]. The phase III TYTAN study compared paclitaxel with or without lapatinib in HER2 positive gastric cancer in the second-line setting in Asian patients [<xref rid="B38" ref-type="bibr">38</xref>]. Median overall survival was 11 months with paclitaxel plus lapatinib compared to 8.9 months with paclitaxel alone (<italic>P</italic> = 0.1044). There was also no significant difference in PFS or TTP. Pertuzumab is a monoclonal antibody which binds to HER2 preventing its dimerization with other HER receptors [<xref rid="B39" ref-type="bibr">39</xref>]. It is currently the subject of a phase III trial (JACOB) comparing pertuzumab/trastuzumab + chemotherapy to pertuzumab + chemotherapy [<xref rid="B40" ref-type="bibr">40</xref>]. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining trastuzumab and DM1 which is a cytotoxic/microtubule polymerization agent [<xref rid="B41" ref-type="bibr">41</xref>]. T-DM1 binds to the HER2 receptor resulting in internalization of the DM1-receptor complex which results in the inhibition of cell division/growth and ultimately cell death [<xref rid="B42" ref-type="bibr">42</xref>]. The ongoing GATSBY trial is currently investigating T-DM1 versus a taxane in patients with previously treated HER2-positive metastatic or locally advanced gastric cancer [<xref rid="B43" ref-type="bibr">43</xref>].</p></sec><sec id="sec5.2"><title>5.2. EGFR</title><p>The epidermal growth factor receptor (EGFR) is known to play an important role in the initiation of signaling transduction cascades via phosphorylation of numerous cellular proteins [<xref rid="B44" ref-type="bibr">44</xref>]. A meta-analysis of 7 studies concluded that EGFR expression correlates with decreased survival in gastric cancer [<xref rid="B45" ref-type="bibr">45</xref>]. In addition, preclinical data suggest that a subset of gastric cancers (20%) with EGFR amplification and overexpression can respond to cetuximab therapy [<xref rid="B46" ref-type="bibr">46</xref>]. Cetuximab is a monoclonal antibody directed against the EGFR receptor and was shown to improve outcomes in<italic> kras</italic> wild-type metastatic colorectal cancer [<xref rid="B47" ref-type="bibr">47</xref>]. The EXPAND study was a phase III trial which studied capecitabine and cisplatin with or without cetuximab in the first line setting in advanced gastric cancer [<xref rid="B48" ref-type="bibr">48</xref>]. Median PFS for chemotherapy/cetuximab was 4.4 months versus 5.6 months for those who received chemotherapy alone (HR = 1.09, 95% CI 0.92&#x02013;1.29, <italic>P</italic> = 0.32). Adding cetuximab to this chemotherapy combination also did not improve overall survival (9.4 months in both arms, HR = 1.0, 95% CI 0.87&#x02013;1.17, <italic>P</italic> = 0.95). The phase III REAL-3 trial compared EOX (epirubicin, oxaliplatin, and capecitabine) with or without panitumumab, a fully human antibody targeting the EGFR receptor [<xref rid="B49" ref-type="bibr">49</xref>]. Median overall survival in the chemotherapy group was 11.3 months compared to chemotherapy + panitumumab which was 8.8 months (HR = 1.37, 95% CI 1.07&#x02013;1.76, <italic>P</italic> = 0.013). An additional EGFR-targeting drug matuzumab also gave disappointing results in advanced esophagogastric cancer [<xref rid="B50" ref-type="bibr">50</xref>]. A combination of ECX chemotherapy/matuzumab failed to improve overall survival (9.4 months for matuzumab group compared with 12.2 months, HR = 1.02, 95% CI 0.61&#x02013;1.70, <italic>P</italic> = 0.945).</p><p>While these results may highlight the lack of importance of the EGFR pathway in esophagogastric cancer, it is important to note that many negative studies were conducted in an unselected population which may explain their negative results.</p></sec><sec id="sec5.3"><title>5.3. C-MET</title><p>C-MET has been proposed as a promising new target in advanced disease and a number of phase III trials are now in progress combining MET inhibitors with chemotherapy in the first-line setting for metastatic gastroesophageal cancer. C-MET is a receptor tyrosine kinase which interacts with its ligand HGF (hepatocyte growth factor) [<xref rid="B51" ref-type="bibr">51</xref>]. It has been found to be dysregulated in gastric cancers and is involved with tumor proliferation, invasion, and angiogenesis and has antiapoptotic functions in cancer cells [<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>]. Tumors which harbor high C-MET expression are more likely to have poor survival rates [<xref rid="B54" ref-type="bibr">54</xref>]. In a recently reported phase II study, the anti-HGF monoclonal antibody rilotumumab was combined with chemotherapy with progression-free survival (PFS) as the primary endpoint. PFS was 5.7 months in rilotumumab treatment arms versus 4.2 months in the placebo group (HR = 0.60, 80% CI 0.45&#x02013;0.79; <italic>P</italic> = 0.016) [<xref rid="B55" ref-type="bibr">55</xref>]. Unfortunately a significant increase in overall survival was not reported although a phase III study is ongoing comparing rilotumumab alone or in combination with cisplatin/capecitabine in the first-line setting [<xref rid="B56" ref-type="bibr">56</xref>]. Tivantinib, although originally regarded as a c-MET inhibitor, has been shown to function independently of the c-MET pathway. Studies on lung cancer cell lines have shown that tivantinib does not inhibit cellular MET activity or downstream phosphorylation of Akt or ERK 1/2 in met-dependent cell lines [<xref rid="B57" ref-type="bibr">57</xref>]. Another preclinical study has shown that tivantinib inhibits microtubule polymerization independent of c-MET [<xref rid="B58" ref-type="bibr">58</xref>]. However, tivantinib has shown promising efficacy as a single agent in a phase II study meriting further study in combination with chemotherapy in a phase III design [<xref rid="B59" ref-type="bibr">59</xref>].</p></sec></sec><sec id="sec6"><title>6. Antiangiogenic Therapy</title><p>Angiogenesis is largely recognized as an important aspect of tumorigenesis and preliminary clinical studies suggested a clinical benefit in the addition of bevacizumab, a monoclonal antibody against VEGF-A, in combination with chemotherapy in gastric cancer [<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>]. The failure of bevacizumab to improve overall survival in the phase III AVAGAST trial was a disappointing development although interestingly it did appear from a subset analysis that a western population may derive some benefit [<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>]. When subset analyses were performed in the AVAGAST trial, it appeared that those with type 3 (distal nondiffuse) gastric cancer and those from European/American populations derived more benefit from bevacizumab than other gastric cancer subtypes or patients from Asian/Pacific populations. The VEGFR-2 (vascular endothelial growth factor receptor-2) antagonist ramucirumab, as reported in the REGARD trial, demonstrated modest activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had disease progression after first-line platinum-containing or fluoropyrimidine-containing chemotherapy [<xref rid="B64" ref-type="bibr">64</xref>]. Median overall survival was 5.2 months (IQR 2.3&#x02013;9.9) in patients in the ramucirumab group and 3.8 months (IQR 1.7&#x02013;7.1) in those in the placebo group (HR = 0.776, 95% CI 0.603&#x02013;0.998; <italic>P</italic> = 0.047). The subsequently reported RAINBOW trial investigated paclitaxel &#x000b1; ramucirumab in patients with metastatic GEJ or gastric adenocarcinoma who had disease progression on or within 4 months after first-line platinum- and fluoropyrimidine-based combination therapy [<xref rid="B65" ref-type="bibr">65</xref>]. The primary endpoint was overall survival (OS). Median OS was 9.63 months for ramucirumab + paclitaxel compared to 7.36 months for paclitaxel alone (HR = 0.807, 95% CI 0.678&#x02013;0.962, <italic>P</italic> = 0.017). Based on these results the combination of ramucirumab + paclitaxel is expected to become a standard of care treatment regimen in the second-line setting for metastatic upper GI tumors. The success of ramucirumab in the 2nd line setting has prompted its clinical investigation in the first line setting. When ramucirumab was combined with FOLFOX in the first-line setting, it did not improve median progression-free survival (6.4 versus 6.7 months, HR = 0.98, 95% CI 0.69&#x02013;1.37, <italic>P</italic> = 0.89) or overall survival (11.7 versus 11.5 months, HR = 1.08, 95% CI 0.73&#x02013;1.58) in patients with advanced gastric/GE junction tumors [<xref rid="B66" ref-type="bibr">66</xref>]. Clinical trials investigating alternative combinations of chemotherapy with ramucirumab in the first-line setting are ongoing.</p><p>Prior to the success of ramucirumab, tyrosine kinase inhibitors had been explored in their roles as antiangiogenic agents in the treatment of esophagogastric tumors. Several tyrosine kinase inhibitors with known antiangiogenic activity are already in use for other tumor types, for example, renal cell cancer. Sunitinib was studied in a phase II trial in patients with advanced gastric or GE junction tumors who had progressed on chemotherapy [<xref rid="B67" ref-type="bibr">67</xref>]. The clinical benefit rate was 7.7% with 32.1% of patients exhibiting disease stability. By intent-to-treat analysis, median overall survival was 6.8 months (95% CI 4.4&#x02013;9.7 months). The addition of docetaxel to sunitinib resulted in a higher objective response rate (41.1% versus 14.3%, <italic>P</italic> = 0.02) although this study did not meet its primary endpoint of prolonging time-to-progression [<xref rid="B68" ref-type="bibr">68</xref>]. Sorafenib, a multitarget TKI of BRAF, VEGF, and PDGFR, was combined with oxaliplatin in a phase II trial in patients who had progressed on first-line cisplatin/fluoropyrimidine chemotherapy [<xref rid="B69" ref-type="bibr">69</xref>]. This study did not meet its primary endpoint of efficacy and showed median PFS of 3 months (95% CI 2.3&#x02013;4.1 months) and median overall survival of 6.5 months (95% CI 5.2&#x02013;9.6 months).</p></sec><sec id="sec7"><title>7. Cancer Cell Stemness</title><p>The characteristic of cancer cells' ability to grow indefinitely has led to the theory that they share common underlying mechanisms with stem cells [<xref rid="B70" ref-type="bibr">70</xref>]. BB1608 is an orally available cancer cell stemness inhibitor whose exact target has not been elucidated [<xref rid="B71" ref-type="bibr">71</xref>]. It has been shown to inhibit the Stat3, <italic>&#x003b2;</italic>-catenin, and Nanog pathways. To date, a phase Ib study has been conducted combining BB1608 and paclitaxel in advanced cancers and of 5 patients enrolled with refractory gastric/GEJ tumors, 2 had partial responses, 1 had stable disease with 25% regression, and 2 had prolonged disease stability &#x02265;24 weeks.</p></sec><sec id="sec8"><title>8. Hedgehog Inhibitors</title><p>The sonic hedgehog (SHH) pathway is crucial for normal cell differentiation and aberrant function affects gastric cell proliferation, migration, and invasion [<xref rid="B72" ref-type="bibr">72</xref>]. A phase II trial combined vismodegib (SHH pathway inhibitor) with FOLFOX in patients with advanced gastric and GE junction tumors [<xref rid="B73" ref-type="bibr">73</xref>]. Patients were treated in the first-line setting and the primary endpoint of median PFS was not met in the intention-to-treat population (11.5 months for FOLFOX/vismodegib versus 9.3 months for FOLFOX alone, 95% CI 8.5&#x02013;14.4, <italic>P</italic> = 0.34). However, the expression of CD44, a gastric cancer stem cell marker, was associated with improved survival in the group who received the SHH inhibitor suggesting that SHH inhibition may only be effective in those with high CD44 expression [<xref rid="B74" ref-type="bibr">74</xref>].</p></sec><sec id="sec9"><title>9. IGFR Targeted Therapy</title><p>Insulin-like growth factors (IGF) are potent hormones which regulate cell proliferation, differentiation, and survival via endocrine, paracrine, and autocrine pathways [<xref rid="B75" ref-type="bibr">75</xref>]. Increased IGF-1R signaling, a ubiquitously expressed tyrosine kinase receptor, is associated with downstream activation of MAPK/PI3K and is supportive for tumor growth [<xref rid="B76" ref-type="bibr">76</xref>]. Cixutumumab, a fully human IgG1 monoclonal antibody specifically targeting IGF-1R, has shown promising antiproliferative activity<italic> in vitro</italic> and clinically, in soft tissue sarcomas [<xref rid="B77" ref-type="bibr">77</xref>]. Cixutumumab was combined with paclitaxel in metastatic esophageal/GE junction cancer in a randomized phase II study [<xref rid="B78" ref-type="bibr">78</xref>]. The primary endpoint (PFS) was not met with median PFS reaching 2.6 months for paclitaxel alone and 2.3 months for paclitaxel + cixutumumab (90% CI 2&#x02013;3.6 months, <italic>P</italic> = 0.72).</p></sec><sec id="sec10"><title>10. Plk-1 Targeted Therapy</title><p>Human polo-like kinase 1 (Plk-1) plays a pivotal role in mitosis in normal and malignant cells and preclinical studies have highlighted the importance of Plk-1 in tumor development [<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>]. Plk-1 is overexpressed in gastric tumor tissue and is associated with worse prognosis [<xref rid="B81" ref-type="bibr">81</xref>]. Volasertib (BI 6727) is a potent Plk-1 inhibitor which induces cell cycle arrest and apoptosis and was administered in combination with an angiokinase inhibitor Nintedanib (BIBF 1120) in a phase I dose-escalation study. This found that it was well-tolerated and a single patient with gastric cancer achieved a partial response [<xref rid="B82" ref-type="bibr">82</xref>].</p></sec><sec id="sec11"><title>11. FGFR Therapy</title><p>Amplification of the FGFR2 (fibroblast growth factor receptor 2) has been associated with tumorigenesis and results in downstream activation of the MAPK/PI3K pathways [<xref rid="B83" ref-type="bibr">83</xref>]. The overexpression of members of the FGF family has been associated with tumor progression/metastasis and is associated with poor survival in gastric cancer [<xref rid="B84" ref-type="bibr">84</xref>]. There is currently a phase II trial investigating the effects of dovitinib, a dual VEGF, and FGFR inhibitor, in combination with docetaxel as second-line chemotherapy in gastric cancer [<xref rid="B85" ref-type="bibr">85</xref>].</p></sec><sec id="sec12"><title>12. PI3K/mTOR Therapy</title><p>The PI3K (phosphatidylinositol 3-kinase) pathway usually becomes activated through growth factor stimulation by EGFR, PDGFR, IGFR, or c-Met [<xref rid="B86" ref-type="bibr">86</xref>]. Once PI3K is activated, Akt becomes phosphorylated affecting cell cycle progression and angiogenesis and has antiapoptotic effects [<xref rid="B87" ref-type="bibr">87</xref>]. The mTOR pathway is a central kinase pathway that increases the production of proteins which regulate key cellular processes including metabolism, angiogenesis, and cell growth [<xref rid="B88" ref-type="bibr">88</xref>]. Phosphorylated mTOR, indicating constitutive activation, has been associated with tumor progression and worse prognosis in gastric cancer patients [<xref rid="B89" ref-type="bibr">89</xref>]. Genetic alterations affecting the PI3K/Akt/mTOR pathway are frequently found in gastric cancer [<xref rid="B90" ref-type="bibr">90</xref>&#x02013;<xref rid="B92" ref-type="bibr">92</xref>]. There are several potential approaches to inhibit aberrant PI3K/Akt/mTOR signaling including specifically targeting a single component of the pathway, for example, mTOR inhibitors, or dual inhibitors, for example, dual PI3K/mTOR inhibitors. A phase Ib trial has been completed combining a PI3K inhibitor BYL719 with a HSP inhibitor AUY922 in metastatic gastric cancer patients whose tumors are HER2 amplified or who harbor a PI3K mutation [<xref rid="B93" ref-type="bibr">93</xref>]. Everolimus, an oral mTOR inhibitor, was investigated in advanced gastric cancer in the GRANITE-1 study [<xref rid="B94" ref-type="bibr">94</xref>]. Patients who had progressed after 1-2 lines of chemotherapy were randomized to receive everolimus or best supportive care (BSC). Median overall survival was 5.4 months with everolimus and 4.3 months with BSC (HR = 0.90, 95% CI 0.75&#x02013;1.08, <italic>P</italic> = 0.124). There are also several ongoing trials comparing everolimus with chemotherapy (paclitaxel, capecitabine, and oxaliplatin) [<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>].</p></sec><sec id="sec13"><title>13. Clinical Trial Design in Gastroesophageal Cancer</title><p>Many of the clinical trials involving molecularly targeted agents in gastroesophageal cancer have had initially promising results which do not persist later in larger phase II/III studies. Numbers of participants in these trials are small relative to other tumor types (e.g., breast or colon cancer) and this may explain, in part, the negative results. However, for the large part, these trials have been conducted in an unselected population. Designing clinical trials based on molecularly selected populations whose tumors overexpress a particular molecular marker, makes it more challenging to accrue, but represents a more meaningful approach. The PANGEA study (personalized antibodies for gastroesophageal adenocarcinoma) is an example of a trial that will prospectively determine whether assigning patients to targeted therapies based on the molecular profiling of their tumors, will impact median overall survival [<xref rid="B97" ref-type="bibr">97</xref>]. This innovative study design may represent the future of targeted therapy evaluation in gastroesophageal cancer where a variety of targeted therapies are now available to patients based on the individual molecular biology of their tumor.</p></sec><sec id="sec14"><title>14. Conclusion</title><p>The development of new therapies for advanced gastroesophageal cancer has been slow compared to other common tumors. Upper GI tumors represent diverse and heterogeneous diseases with multiple etiological factors including viral and bacterial infection via EBV and<italic> Helicobacter pylori</italic>, inherited familial syndromes, and other risk factors including diet, smoking, and alcohol consumption. Taken together, upper GI tumors are second only to lung cancer in terms of cancer related morbidity. In recent years incremental breakthroughs in our understanding of the molecular biology underlying the development of these cancers have taken place and these findings are now being translated into clinical research. High density genomic profiling arrays analyzing somatic copy-number alterations in gastroesophageal cancers have identified amplified genes in 37% of tumors, most notably,<italic> ERBB2</italic>,<italic> FGFR1</italic>,<italic> FGFR2</italic>,<italic> EGFR</italic>, and<italic> MET</italic> [<xref rid="B27" ref-type="bibr">27</xref>]. Until recently however the &#x0201c;one-size fits all approach&#x0201d; to enrolling patients on clinical trials has failed in gastroesophageal cancer as it has in other tumor types.</p><p>The Cancer Genome Atlas Research Network has recently identified other viable targets and it appears likely that the four molecular subtypes of gastric cancer described in this study should advance clinical research in the years to come. In addition to targeted agents there has been a rapid expansion in our understanding of the immune environment changes that occur in these tumors allowing them to avoid immune-editing. Future studies may combine targeted therapeutics with immunotherapies such as checkpoint inhibitors. Patient selection should be performed in all clinical trials to ensure that molecularly targeted therapies can fulfill their promise in upper GI tumors.</p></sec></body><back><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2014</article-title><source><italic>CA: Cancer Journal for Clinicians</italic></source><year>2014</year><volume>64</volume><issue>1</issue><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3322/caac.21208</pub-id><pub-id pub-id-type="other">2-s2.0-84892805731</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Shin</surname><given-names>H.-R.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Forman</surname><given-names>D.</given-names></name><name><surname>Mathers</surname><given-names>C.</given-names></name><name><surname>Parkin</surname><given-names>D. M.</given-names></name></person-group><article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title><source><italic>International Journal of Cancer</italic></source><year>2010</year><volume>127</volume><issue>12</issue><fpage>2893</fpage><lpage>2917</lpage><pub-id pub-id-type="other">2-s2.0-78049485263</pub-id><pub-id pub-id-type="doi">10.1002/ijc.25516</pub-id><pub-id pub-id-type="pmid">21351269</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crew</surname><given-names>K. D.</given-names></name><name><surname>Neugut</surname><given-names>A. I.</given-names></name></person-group><article-title>Epidemiology of upper gastrointestinal malignancies</article-title><source><italic>Seminars in Oncology</italic></source><year>2004</year><volume>31</volume><issue>4</issue><fpage>450</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2004.04.021</pub-id><pub-id pub-id-type="other">2-s2.0-4043144935</pub-id><pub-id pub-id-type="pmid">15297938</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>D.</given-names></name></person-group><article-title>An international association between <italic>Helicobacter pylori</italic> infection and gastric cancer. The EUROGAST Study Group</article-title><source><italic>The Lancet</italic></source><year>1993</year><volume>341</volume><issue>8857</issue><fpage>1359</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90938-d</pub-id><pub-id pub-id-type="other">2-s2.0-0027176157</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubenstein</surname><given-names>J. H.</given-names></name><name><surname>Taylor</surname><given-names>J. B.</given-names></name></person-group><article-title>Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2010</year><volume>32</volume><issue>10</issue><fpage>1222</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2010.04471.x</pub-id><pub-id pub-id-type="other">2-s2.0-78249263541</pub-id><pub-id pub-id-type="pmid">20955441</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H.</given-names></name><name><surname>Abraham</surname><given-names>N. S.</given-names></name><name><surname>El-Serag</surname><given-names>H. B.</given-names></name></person-group><article-title>Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2005</year><volume>143</volume><issue>3</issue><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-143-3-200508020-00006</pub-id><pub-id pub-id-type="other">2-s2.0-23044493202</pub-id><pub-id pub-id-type="pmid">16061918</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D.</given-names></name><name><surname>Starling</surname><given-names>N.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2008</year><volume>358</volume><issue>1</issue><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1056/nejmoa073149</pub-id><pub-id pub-id-type="other">2-s2.0-38049047178</pub-id><pub-id pub-id-type="pmid">18172173</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overman</surname><given-names>M. J.</given-names></name><name><surname>Kazmi</surname><given-names>S. M.</given-names></name><name><surname>Jhamb</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer</article-title><source><italic>Cancer</italic></source><year>2010</year><volume>116</volume><issue>6</issue><fpage>1446</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1002/cncr.24925</pub-id><pub-id pub-id-type="other">2-s2.0-77949414964</pub-id><pub-id pub-id-type="pmid">20108336</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebbutt</surname><given-names>N. C.</given-names></name><name><surname>Cummins</surname><given-names>M. M.</given-names></name><name><surname>Sourjina</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial</article-title><source><italic>British Journal of Cancer</italic></source><year>2010</year><volume>102</volume><issue>3</issue><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605522</pub-id><pub-id pub-id-type="other">2-s2.0-76349088039</pub-id><pub-id pub-id-type="pmid">20068567</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M. A.</given-names></name><name><surname>Shibata</surname><given-names>S.</given-names></name><name><surname>Stoller</surname><given-names>R. G.</given-names></name><etal/></person-group><article-title>Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE)</article-title><volume>28</volume><conf-name>ASCO Meeting Abstracts</conf-name><conf-date>2014</conf-date><fpage>p. 4014</fpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>H. E. R.</given-names></name><name><surname>Marshall</surname><given-names>A.</given-names></name><name><surname>Bridgewater</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial</article-title><source><italic>The Lancet Oncology</italic></source><year>2014</year><volume>15</volume><issue>1</issue><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="other">2-s2.0-84891371156</pub-id><pub-id pub-id-type="doi">10.1016/s1470-2045(13)70549-7</pub-id><pub-id pub-id-type="pmid">24332238</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. S.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><etal/></person-group><article-title>Second-line chemotherapy versus supportive cancertreatment in advanced gastric cancer: a meta-analysis</article-title><source><italic>Annals of Oncology</italic></source><year>2013</year><volume>24</volume><issue>11</issue><fpage>2850</fpage><lpage>2854</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt351</pub-id><pub-id pub-id-type="other">2-s2.0-84887116455</pub-id><pub-id pub-id-type="pmid">23942775</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkes</surname><given-names>E.</given-names></name><name><surname>Okines</surname><given-names>A. F. C.</given-names></name><name><surname>Papamichael</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer</article-title><source><italic>European Journal of Cancer</italic></source><year>2011</year><volume>47</volume><issue>8</issue><fpage>1146</fpage><lpage>1151</lpage><pub-id pub-id-type="other">2-s2.0-79955534227</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2010.12.021</pub-id><pub-id pub-id-type="pmid">21269822</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hironaka</surname><given-names>S.</given-names></name><name><surname>Zenda</surname><given-names>S.</given-names></name><name><surname>Boku</surname><given-names>N.</given-names></name><name><surname>Fukutomi</surname><given-names>A.</given-names></name><name><surname>Yoshino</surname><given-names>T.</given-names></name><name><surname>Onozawa</surname><given-names>Y.</given-names></name></person-group><article-title>Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer</article-title><source><italic>Gastric Cancer</italic></source><year>2006</year><volume>9</volume><issue>1</issue><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="other">2-s2.0-33645235645</pub-id><pub-id pub-id-type="doi">10.1007/s10120-005-0351-6</pub-id><pub-id pub-id-type="pmid">16557431</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussioutas</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer</article-title><source><italic>Cancer Research</italic></source><year>2003</year><volume>63</volume><issue>10</issue><fpage>2569</fpage><lpage>2577</lpage><pub-id pub-id-type="other">2-s2.0-0038576352</pub-id><pub-id pub-id-type="pmid">12750281</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>I. B.</given-names></name><name><surname>Ivanova</surname><given-names>T.</given-names></name><name><surname>Lim</surname><given-names>K. H.</given-names></name><etal/></person-group><article-title>Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy</article-title><source><italic>Gastroenterology</italic></source><year>2011</year><volume>141</volume><issue>2</issue><fpage>476</fpage><lpage>485, 485 e1&#x02013;11</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.04.042</pub-id><pub-id pub-id-type="other">2-s2.0-80051486834</pub-id><pub-id pub-id-type="pmid">21684283</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Z.</given-names></name><name><surname>Tan</surname><given-names>I. B.</given-names></name><name><surname>Das</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracil</article-title><source><italic>Gastroenterology</italic></source><year>2013</year><volume>145</volume><issue>3</issue><fpage>554</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.05.010</pub-id><pub-id pub-id-type="other">2-s2.0-84883185766</pub-id><pub-id pub-id-type="pmid">23684942</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><collab>The Cancer Genome Atlas Research Network</collab><article-title>Comprehensive molecular characterization of gastric adenocarcinoma</article-title><source><italic>Nature</italic></source><year>2014</year><volume>513</volume><issue>7517</issue><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nature13480</pub-id><pub-id pub-id-type="pmid">25079317</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Ajani</surname><given-names>J. A.</given-names></name><name><surname>Hawk</surname><given-names>E. T.</given-names></name><etal/></person-group><article-title>Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis</article-title><source><italic>Cancer Prevention Research</italic></source><year>2010</year><volume>3</volume><issue>9</issue><fpage>1176</fpage><lpage>1186</lpage><pub-id pub-id-type="other">2-s2.0-77956402130</pub-id><pub-id pub-id-type="doi">10.1158/1940-6207.capr-09-0265</pub-id><pub-id pub-id-type="pmid">20651033</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varis</surname><given-names>A.</given-names></name><name><surname>Puolakkainen</surname><given-names>P.</given-names></name><name><surname>Savolainen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma</article-title><source><italic>Cancer Genetics and Cytogenetics</italic></source><year>2001</year><volume>127</volume><issue>1</issue><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/s0165-4608(00)00423-4</pub-id><pub-id pub-id-type="other">2-s2.0-0035333654</pub-id><pub-id pub-id-type="pmid">11408066</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>B. J.</given-names></name><name><surname>Prevo</surname><given-names>L. J.</given-names></name><name><surname>Galipeau</surname><given-names>P. C.</given-names></name><etal/></person-group><article-title>Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression</article-title><source><italic>The American Journal of Gastroenterology</italic></source><year>2001</year><volume>96</volume><issue>10</issue><fpage>2839</fpage><lpage>2848</lpage><pub-id pub-id-type="doi">10.1016/s0002-9270(01)02798-8</pub-id><pub-id pub-id-type="other">2-s2.0-0034793846</pub-id><pub-id pub-id-type="pmid">11693316</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollstein</surname><given-names>M. C.</given-names></name><name><surname>Metcalf</surname><given-names>R. A.</given-names></name><name><surname>Welsh</surname><given-names>J. A.</given-names></name><name><surname>Montesano</surname><given-names>R.</given-names></name><name><surname>Harris</surname><given-names>C. C.</given-names></name></person-group><article-title>Frequent mutation of the p53 gene in human esophageal cancer</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1990</year><volume>87</volume><issue>24</issue><fpage>9958</fpage><lpage>9961</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.24.9958</pub-id><pub-id pub-id-type="other">2-s2.0-0025599928</pub-id><pub-id pub-id-type="pmid">2263646</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casson</surname><given-names>A. G.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>T.</given-names></name><name><surname>Cleary</surname><given-names>K. R.</given-names></name><name><surname>Ro</surname><given-names>J. Y.</given-names></name><name><surname>Levin</surname><given-names>B.</given-names></name><name><surname>Roth</surname><given-names>J. A.</given-names></name></person-group><article-title>p53 gene mutations in Barrett's epithelium and esophageal cancer</article-title><source><italic>Cancer Research</italic></source><year>1991</year><volume>51</volume><issue>16</issue><fpage>4495</fpage><lpage>4499</lpage><pub-id pub-id-type="other">2-s2.0-0025989468</pub-id><pub-id pub-id-type="pmid">1868473</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>E. L.</given-names></name><name><surname>Leoni</surname><given-names>L. M.</given-names></name><name><surname>Canto</surname><given-names>M. I.</given-names></name><etal/></person-group><article-title>Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications</article-title><source><italic>The American Journal of Surgical Pathology</italic></source><year>2005</year><volume>29</volume><issue>11</issue><fpage>1497</fpage><lpage>1504</lpage><pub-id pub-id-type="other">2-s2.0-27244449307</pub-id><pub-id pub-id-type="doi">10.1097/01.pas.0000170349.47680.e8</pub-id><pub-id pub-id-type="pmid">16224217</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abeloff</surname><given-names>M. D.</given-names></name><name><surname>Eggleston</surname><given-names>J. C.</given-names></name><name><surname>Mendelsohn</surname><given-names>G.</given-names></name><name><surname>Ettinger</surname><given-names>D. S.</given-names></name><name><surname>Baylin</surname><given-names>S. B.</given-names></name></person-group><article-title>Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. A clinicopathologic study</article-title><source><italic>The American Journal of Medicine</italic></source><year>1979</year><volume>66</volume><issue>5</issue><fpage>757</fpage><lpage>764</lpage><pub-id pub-id-type="other">2-s2.0-0018777121</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(79)91113-6</pub-id><pub-id pub-id-type="pmid">220872</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>N.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Bettegowda</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma</article-title><source><italic>Cancer Discovery</italic></source><year>2012</year><volume>2</volume><issue>10</issue><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0189</pub-id><pub-id pub-id-type="other">2-s2.0-84867398217</pub-id><pub-id pub-id-type="pmid">22877736</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulak</surname><given-names>A. M.</given-names></name><name><surname>Schumacher</surname><given-names>S. E.</given-names></name><name><surname>van Lieshout</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis</article-title><source><italic>Cancer Research</italic></source><year>2012</year><volume>72</volume><issue>17</issue><fpage>4383</fpage><lpage>4393</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-11-3893</pub-id><pub-id pub-id-type="other">2-s2.0-84865238936</pub-id><pub-id pub-id-type="pmid">22751462</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olayioye</surname><given-names>M. A.</given-names></name></person-group><article-title>Update on HER-2 as a target for cancer therapy&#x02014;intracellular signaling pathways of ErbB2/HER-2 and family members</article-title><source><italic>Breast Cancer Research</italic></source><year>2001</year><volume>3</volume><issue>6</issue><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1186/bcr327</pub-id><pub-id pub-id-type="other">2-s2.0-2342488965</pub-id><pub-id pub-id-type="pmid">11737890</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>M.</given-names></name><name><surname>Hollm&#x000e9;n</surname><given-names>M.</given-names></name><name><surname>Junttila</surname><given-names>T. T.</given-names></name><etal/></person-group><article-title>Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II<italic>&#x003b1;</italic> gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab</article-title><source><italic>Annals of Oncology</italic></source><year>2005</year><volume>16</volume><issue>2</issue><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="other">2-s2.0-20044372721</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdi064</pub-id><pub-id pub-id-type="pmid">15668283</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>D. I.</given-names></name><name><surname>Yun</surname><given-names>J. W.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><etal/></person-group><article-title>HER-2/neu amplification is an independent prognostic factor in gastric cancer</article-title><source><italic>Digestive Diseases and Sciences</italic></source><year>2006</year><volume>51</volume><issue>8</issue><fpage>1371</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1007/s10620-005-9057-1</pub-id><pub-id pub-id-type="pmid">16868827</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janjigian</surname><given-names>Y. Y.</given-names></name><name><surname>Werner</surname><given-names>D.</given-names></name><name><surname>Pauligk</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis</article-title><source><italic>Annals of Oncology</italic></source><year>2012</year><volume>23</volume><issue>10</issue><fpage>2656</fpage><lpage>2662</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds104</pub-id><pub-id pub-id-type="other">2-s2.0-84867131579</pub-id><pub-id pub-id-type="pmid">22689179</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Martin</surname><given-names>C.</given-names></name><name><surname>Garralda</surname><given-names>E.</given-names></name><name><surname>Echarri</surname><given-names>M. J.</given-names></name><etal/></person-group><article-title>HER2/<italic>neu</italic> testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer</article-title><source><italic>Journal of Clinical Pathology</italic></source><year>2012</year><volume>65</volume><issue>8</issue><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2012-200774</pub-id><pub-id pub-id-type="other">2-s2.0-84864551756</pub-id><pub-id pub-id-type="pmid">22569536</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>Y.-J.</given-names></name><name><surname>Van Cutsem</surname><given-names>E.</given-names></name><name><surname>Feyereislova</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title><source><italic>The Lancet</italic></source><year>2010</year><volume>376</volume><issue>9742</issue><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61121-X</pub-id><pub-id pub-id-type="other">2-s2.0-77958099652</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhirsch</surname><given-names>A.</given-names></name><name><surname>Gelber</surname><given-names>R. D.</given-names></name><name><surname>Piccart-Gebhart</surname><given-names>M. J.</given-names></name><etal/></person-group><article-title>2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial</article-title><source><italic>The Lancet</italic></source><year>2013</year><volume>382</volume><issue>9897</issue><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(13)61094-6</pub-id><pub-id pub-id-type="other">2-s2.0-84884418164</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Minckwitz</surname><given-names>G.</given-names></name><name><surname>Schwedler</surname><given-names>K.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer</article-title><source><italic>European Journal of Cancer</italic></source><year>2011</year><volume>47</volume><issue>15</issue><fpage>2273</fpage><lpage>2281</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.06.021</pub-id><pub-id pub-id-type="other">2-s2.0-80053362290</pub-id><pub-id pub-id-type="pmid">21741829</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>D.</given-names></name><name><surname>Satoh</surname><given-names>T.</given-names></name><name><surname>Kurokawa</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5)</article-title><source><italic>Japanese Journal of Clinical Oncology</italic></source><year>2013</year><volume>43</volume><issue>8</issue><fpage>838</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyt083</pub-id><pub-id pub-id-type="other">2-s2.0-84881089659</pub-id><pub-id pub-id-type="pmid">23852648</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>E. R.</given-names></name><name><surname>Truesdale</surname><given-names>A. T.</given-names></name><name><surname>McDonald</surname><given-names>O. B.</given-names></name><etal/></person-group><article-title>A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</article-title><source><italic>Cancer Research</italic></source><year>2004</year><volume>64</volume><issue>18</issue><fpage>6652</fpage><lpage>6659</lpage><pub-id pub-id-type="other">2-s2.0-4644289313</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.can-04-1168</pub-id><pub-id pub-id-type="pmid">15374980</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>R.-H.</given-names></name><name><surname>Chung</surname><given-names>H. C.</given-names></name><etal/></person-group><article-title>Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN&#x02013;a randomized, phase III study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2014</year><volume>32</volume><issue>19</issue><fpage>2039</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1200/jco.2013.53.6136</pub-id><pub-id pub-id-type="pmid">24868024</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>C. W.</given-names></name><name><surname>Allison</surname><given-names>D. E.</given-names></name><name><surname>Flagella</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab</article-title><source><italic>Cancer Immunology, Immunotherapy</italic></source><year>2006</year><volume>55</volume><issue>6</issue><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1007/s00262-005-0058-x</pub-id><pub-id pub-id-type="other">2-s2.0-33644600485</pub-id><pub-id pub-id-type="pmid">16151804</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabernero</surname><given-names>J.</given-names></name><name><surname>Marcelo Hoff</surname><given-names>P.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB)</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2013</year><comment>abstr TPS4150</comment></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LoRusso</surname><given-names>P. M.</given-names></name><name><surname>Weiss</surname><given-names>D.</given-names></name><name><surname>Guardino</surname><given-names>E.</given-names></name><name><surname>Girish</surname><given-names>S.</given-names></name><name><surname>Sliwkowski</surname><given-names>M. X.</given-names></name></person-group><article-title>Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer</article-title><source><italic>Clinical Cancer Research</italic></source><year>2011</year><volume>17</volume><issue>20</issue><fpage>6437</fpage><lpage>6447</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-11-0762</pub-id><pub-id pub-id-type="other">2-s2.0-80054092983</pub-id><pub-id pub-id-type="pmid">22003071</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>H. K.</given-names></name><name><surname>Park</surname><given-names>P. U.</given-names></name><name><surname>Widdison</surname><given-names>W. C.</given-names></name><etal/></person-group><article-title>Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</article-title><source><italic>Cancer Research</italic></source><year>2006</year><volume>66</volume><issue>8</issue><fpage>4426</fpage><lpage>4433</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4489</pub-id><pub-id pub-id-type="other">2-s2.0-33645500289</pub-id><pub-id pub-id-type="pmid">16618769</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="gov"><collab>UK Clinical Research Network Study Portfolio</collab><article-title>NCRN369: GATSBY TDM1 vs taxane in previously treated advanced HER2+ gastric ca</article-title><source><italic>UKCRN</italic></source><issue>12204</issue><comment><ext-link ext-link-type="uri" xlink:href="http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12204">http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12204</ext-link></comment></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthuswamy</surname><given-names>S. K.</given-names></name><name><surname>Gilman</surname><given-names>M.</given-names></name><name><surname>Brugge</surname><given-names>J. S.</given-names></name></person-group><article-title>Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>1999</year><volume>19</volume><issue>10</issue><fpage>6845</fpage><lpage>6857</lpage><pub-id pub-id-type="other">2-s2.0-0032860819</pub-id><pub-id pub-id-type="pmid">10490623</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>J.-M.</given-names></name><name><surname>Hu</surname><given-names>T.-T.</given-names></name><etal/></person-group><article-title>Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis</article-title><source><italic>Archives of Medical Research</italic></source><year>2013</year><volume>44</volume><issue>5</issue><fpage>380</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2013.07.001</pub-id><pub-id pub-id-type="other">2-s2.0-84883401358</pub-id><pub-id pub-id-type="pmid">23871709</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy</article-title><source><italic>Scientific Reports</italic></source><year>2013</year><volume>3, article 2992</volume><pub-id pub-id-type="doi">10.1038/srep02992</pub-id><pub-id pub-id-type="other">2-s2.0-84886299562</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E.</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>C.-H.</given-names></name><name><surname>L&#x000e1;ng</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2011</year><volume>29</volume><issue>15</issue><fpage>2011</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1200/jco.2010.33.5091</pub-id><pub-id pub-id-type="other">2-s2.0-79956298812</pub-id><pub-id pub-id-type="pmid">21502544</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lordick</surname><given-names>F.</given-names></name><name><surname>Kang</surname><given-names>Y.-K.</given-names></name><name><surname>Chung</surname><given-names>H.-C.</given-names></name><etal/></person-group><article-title>Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial</article-title><source><italic>The Lancet Oncology</italic></source><year>2013</year><volume>14</volume><issue>6</issue><fpage>490</fpage><lpage>499</lpage><pub-id pub-id-type="other">2-s2.0-84876951761</pub-id><pub-id pub-id-type="doi">10.1016/s1470-2045(13)70102-5</pub-id><pub-id pub-id-type="pmid">23594786</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waddell</surname><given-names>T.</given-names></name><name><surname>Chau</surname><given-names>I.</given-names></name><name><surname>Cunningham</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial</article-title><source><italic>The Lancet Oncology</italic></source><year>2013</year><volume>14</volume><issue>6</issue><fpage>481</fpage><lpage>489</lpage><pub-id pub-id-type="other">2-s2.0-84876992498</pub-id><pub-id pub-id-type="doi">10.1016/s1470-2045(13)70096-2</pub-id><pub-id pub-id-type="pmid">23594787</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Starling</surname><given-names>N.</given-names></name><name><surname>Cunningham</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study</article-title><source><italic>Annals of Oncology</italic></source><year>2010</year><volume>21</volume><issue>11</issue><fpage>2213</fpage><lpage>2219</lpage><pub-id pub-id-type="other">2-s2.0-77958496605</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdq247</pub-id><pub-id pub-id-type="pmid">20497967</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Kataoka</surname><given-names>H.</given-names></name><name><surname>Goto</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue</article-title><source><italic>Cancer Science</italic></source><year>2004</year><volume>95</volume><issue>10</issue><fpage>803</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb02185.x</pub-id><pub-id pub-id-type="other">2-s2.0-9144251036</pub-id><pub-id pub-id-type="pmid">15504247</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrotto</surname><given-names>P.</given-names></name><name><surname>Valdembri</surname><given-names>D.</given-names></name><name><surname>Corso</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Sema4D induces angiogenesis through Met recruitment by Plexin B1</article-title><source><italic>Blood</italic></source><year>2005</year><volume>105</volume><issue>11</issue><fpage>4321</fpage><lpage>4329</lpage><pub-id pub-id-type="other">2-s2.0-19344364598</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-07-2885</pub-id><pub-id pub-id-type="pmid">15632204</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T.-J.</given-names></name><name><surname>Wang</surname><given-names>J.-Y.</given-names></name><name><surname>Lin</surname><given-names>S.-R.</given-names></name><name><surname>Lian</surname><given-names>S.-T.</given-names></name><name><surname>Hsieh</surname><given-names>J.-S.</given-names></name></person-group><article-title>Overexpression of the c-met protooncogene in human gastric carcinoma&#x02014;correlation to clinical features</article-title><source><italic>Acta Oncologica</italic></source><year>2001</year><volume>40</volume><issue>5</issue><fpage>638</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1080/028418601750444204</pub-id><pub-id pub-id-type="other">2-s2.0-0034789096</pub-id><pub-id pub-id-type="pmid">11669338</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>N.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name></person-group><article-title>c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis</article-title><source><italic>PLoS ONE</italic></source><year>2013</year><volume>8</volume><issue>11</issue><pub-id pub-id-type="publisher-id">e79137</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0079137</pub-id><pub-id pub-id-type="other">2-s2.0-84892394160</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iveson</surname><given-names>T.</given-names></name><name><surname>Donehower</surname><given-names>R. C.</given-names></name><name><surname>Davidenko</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study</article-title><source><italic>The Lancet Oncology</italic></source><year>2014</year><volume>15</volume><issue>9</issue><fpage>1007</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(14)70023-3</pub-id><pub-id pub-id-type="pmid">24965569</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="other"><comment>A Phase 3 Study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (RILOMET-2), NCT02137343, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02137343">http://clinicaltrials.gov/show/NCT02137343</ext-link></comment></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calles</surname><given-names>A.</given-names></name><name><surname>Kwiatkowski</surname><given-names>N.</given-names></name><name><surname>Cammarata</surname><given-names>B. K.</given-names></name><name><surname>Ercan</surname><given-names>D.</given-names></name><name><surname>Gray</surname><given-names>N. S.</given-names></name><name><surname>J&#x000e4;nne</surname><given-names>P. A.</given-names></name></person-group><article-title>Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines</article-title><source><italic>Molecular Oncology</italic></source><year>2015</year><volume>9</volume><issue>1</issue><fpage>260</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.08.011</pub-id><pub-id pub-id-type="pmid">25226813</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>R.</given-names></name><name><surname>Aoyama</surname><given-names>A.</given-names></name><name><surname>Yamori</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition</article-title><source><italic>Cancer Research</italic></source><year>2013</year><volume>73</volume><issue>10</issue><fpage>3087</fpage><lpage>3096</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-12-3256</pub-id><pub-id pub-id-type="other">2-s2.0-84877848587</pub-id><pub-id pub-id-type="pmid">23598276</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y.-K.</given-names></name><name><surname>Muro</surname><given-names>K.</given-names></name><name><surname>Ryu</surname><given-names>M.-H.</given-names></name><etal/></person-group><article-title>A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer</article-title><source><italic>Investigational New Drugs</italic></source><year>2014</year><volume>32</volume><issue>2</issue><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1007/s10637-013-0057-2</pub-id><pub-id pub-id-type="other">2-s2.0-84896404764</pub-id><pub-id pub-id-type="pmid">24337769</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Gerber</surname><given-names>H.-P.</given-names></name><name><surname>LeCouter</surname><given-names>J.</given-names></name></person-group><article-title>The biology of VEGF and its receptors</article-title><source><italic>Nature Medicine</italic></source><year>2003</year><volume>9</volume><issue>6</issue><fpage>669</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1038/nm0603-669</pub-id><pub-id pub-id-type="other">2-s2.0-0037699954</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M. A.</given-names></name><name><surname>Ramanathan</surname><given-names>R. K.</given-names></name><name><surname>Ilson</surname><given-names>D. H.</given-names></name><etal/></person-group><article-title>Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2006</year><volume>24</volume><issue>33</issue><fpage>5201</fpage><lpage>5206</lpage><pub-id pub-id-type="doi">10.1200/jco.2006.08.0887</pub-id><pub-id pub-id-type="other">2-s2.0-33846629672</pub-id><pub-id pub-id-type="pmid">17114652</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M. A.</given-names></name><name><surname>Van Cutsem</surname><given-names>E.</given-names></name><name><surname>Kang</surname><given-names>Y. K.</given-names></name><etal/></person-group><article-title>Survival analysis according to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2012</year><volume>30</volume><issue>supplement 4, abstract 5</issue></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>A.</given-names></name><name><surname>Shah</surname><given-names>M. A.</given-names></name><name><surname>van Cutsem</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2011</year><volume>29</volume><issue>30</issue><fpage>3968</fpage><lpage>3976</lpage><pub-id pub-id-type="doi">10.1200/jco.2011.36.2236</pub-id><pub-id pub-id-type="other">2-s2.0-80053573446</pub-id><pub-id pub-id-type="pmid">21844504</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>C. S.</given-names></name><name><surname>Tomasek</surname><given-names>J.</given-names></name><name><surname>Yong</surname><given-names>C. J.</given-names></name><etal/></person-group><article-title>Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial</article-title><source><italic>The Lancet</italic></source><year>2014</year><volume>383</volume><issue>9911</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="other">2-s2.0-84892852372</pub-id><pub-id pub-id-type="doi">10.1016/s0140-6736(13)61719-5</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilke</surname><given-names>H.</given-names></name><name><surname>van Cutsem</surname><given-names>E.</given-names></name><name><surname>Oh</surname><given-names>S. C.</given-names></name><etal/></person-group><article-title>RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2014</year><volume>32</volume><issue>supplement 3</issue><comment>Gastrointestinal Cancers Symposium abstract no. LBA7</comment></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H. H.</given-names></name><name><surname>Bendell</surname><given-names>J. C.</given-names></name><name><surname>Braiteh</surname><given-names>F. S.</given-names></name><etal/></person-group><article-title>Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2014</year><volume>32</volume><issue>5s</issue><comment>abstr 4004</comment></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>Y.-J.</given-names></name><name><surname>Kang</surname><given-names>Y.-K.</given-names></name><name><surname>Kang</surname><given-names>W. K.</given-names></name><etal/></person-group><article-title>Phase II study of sunitinib as second-line treatment for advanced gastric cancer</article-title><source><italic>Investigational New Drugs</italic></source><year>2011</year><volume>29</volume><issue>6</issue><fpage>1449</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9438-y</pub-id><pub-id pub-id-type="other">2-s2.0-82955241985</pub-id><pub-id pub-id-type="pmid">20461441</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum</article-title><source><italic>British Journal of Cancer</italic></source><year>2012</year><volume>106</volume><issue>9</issue><fpage>1469</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.100</pub-id><pub-id pub-id-type="other">2-s2.0-84860234330</pub-id><pub-id pub-id-type="pmid">22460270</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Richard</surname><given-names>M.</given-names></name><name><surname>Gallego</surname><given-names>R.</given-names></name><name><surname>Pericay</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study</article-title><source><italic>Investigational New Drugs</italic></source><year>2013</year><volume>31</volume><issue>6</issue><fpage>1573</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1007/s10637-013-0020-2</pub-id><pub-id pub-id-type="other">2-s2.0-84888627652</pub-id><pub-id pub-id-type="pmid">24077981</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>D. J.</given-names></name><name><surname>Segal</surname><given-names>E.</given-names></name><name><surname>Chang</surname><given-names>H. Y.</given-names></name></person-group><article-title>Stemness, cancer and cancer stem cells</article-title><source><italic>Cell Cycle</italic></source><year>2008</year><volume>7</volume><issue>23</issue><fpage>3622</fpage><lpage>3624</lpage><pub-id pub-id-type="doi">10.4161/cc.7.23.7104</pub-id><pub-id pub-id-type="other">2-s2.0-57349107094</pub-id><pub-id pub-id-type="pmid">19029796</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitron</surname><given-names>M.</given-names></name><name><surname>Stephenson</surname><given-names>J.</given-names></name><name><surname>Chi</surname><given-names>K. N.</given-names></name><etal/></person-group><article-title>A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2014</year><volume>32</volume><issue>supplement, abstract 2530</issue></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>S.</given-names></name></person-group><article-title>Characterization of sonic hedgehog inhibition in gastric carcinoma cells</article-title><source><italic>Oncology Letters</italic></source><year>2014</year><volume>7</volume><issue>5</issue><fpage>1381</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.3892/ol.2014.1964</pub-id><pub-id pub-id-type="other">2-s2.0-84896277224</pub-id><pub-id pub-id-type="pmid">24765141</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>D. J.</given-names></name><name><surname>Christos</surname><given-names>P. J.</given-names></name><name><surname>Sparano</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2013</year><volume>31</volume><issue>supplement 4, abstract 67</issue></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>C.</given-names></name><name><surname>Park</surname><given-names>D. J.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><etal/></person-group><article-title>CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance</article-title><source><italic>Clinical Cancer Research</italic></source><year>2014</year><volume>20</volume><issue>15</issue><fpage>3974</fpage><lpage>3988</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-14-0011</pub-id><pub-id pub-id-type="pmid">24947926</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paveli&#x00107;</surname><given-names>K.</given-names></name><name><surname>Kolak</surname><given-names>T.</given-names></name><name><surname>Kapitanovi&#x00107;</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF IR and M6-P/IGF 2R)</article-title><source><italic>The Journal of Pathology</italic></source><year>2003</year><volume>201</volume><issue>3</issue><fpage>430</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1002/path.1465</pub-id><pub-id pub-id-type="other">2-s2.0-0242558942</pub-id><pub-id pub-id-type="pmid">14595755</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>Y. S.</given-names></name><name><surname>Jallal</surname><given-names>B.</given-names></name><name><surname>Viner</surname><given-names>J.</given-names></name></person-group><article-title>Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology</article-title><source><italic>Cancer Research</italic></source><year>2012</year><volume>72</volume><issue>1</issue><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-11-0550</pub-id><pub-id pub-id-type="other">2-s2.0-84855398829</pub-id><pub-id pub-id-type="pmid">22215692</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;ffski</surname><given-names>P.</given-names></name><name><surname>Adkins</surname><given-names>D.</given-names></name><name><surname>Blay</surname><given-names>J.-Y.</given-names></name><etal/></person-group><article-title>An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours</article-title><source><italic>European Journal of Cancer</italic></source><year>2013</year><volume>49</volume><issue>15</issue><fpage>3219</fpage><lpage>3228</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.06.010</pub-id><pub-id pub-id-type="other">2-s2.0-84884910107</pub-id><pub-id pub-id-type="pmid">23835252</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S. J.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Catalano</surname><given-names>P. J.</given-names></name><etal/></person-group><article-title>E2208: randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2014</year><volume>32</volume><issue>5, supplement</issue><comment>ASCO Annual Meeting abstract no. 4020</comment></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>F. A.</given-names></name><name><surname>Sillj&#x000e9;</surname><given-names>H. H. W.</given-names></name><name><surname>Nigg</surname><given-names>E. A.</given-names></name></person-group><article-title>Polo-like kinases and the orchestration of cell division</article-title><source><italic>Nature Reviews Molecular Cell Biology</italic></source><year>2004</year><volume>5</volume><issue>6</issue><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="other">2-s2.0-2942615282</pub-id><pub-id pub-id-type="pmid">15173822</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sp&#x000e4;nkuch-Schmitt</surname><given-names>B.</given-names></name><name><surname>Wolf</surname><given-names>G.</given-names></name><name><surname>Solbach</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells</article-title><source><italic>Oncogene</italic></source><year>2002</year><volume>21</volume><issue>20</issue><fpage>3162</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1038/sj/onc/1205412</pub-id><pub-id pub-id-type="other">2-s2.0-0037046495</pub-id><pub-id pub-id-type="pmid">12082631</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichert</surname><given-names>W.</given-names></name><name><surname>Ullrich</surname><given-names>A.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Expression patterns of polo-like kinase 1 in human gastric cancer</article-title><source><italic>Cancer Science</italic></source><year>2006</year><volume>97</volume><issue>4</issue><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00170.x</pub-id><pub-id pub-id-type="other">2-s2.0-33645340348</pub-id><pub-id pub-id-type="pmid">16630118</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Braud</surname><given-names>F. G.</given-names></name><name><surname>Cascinu</surname><given-names>S.</given-names></name><name><surname>Spitaleri</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2013</year><volume>31</volume><issue>supplement, abstract 2556</issue></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>M.</given-names></name></person-group><article-title>FGF signaling network in the gastrointestinal tract (review)</article-title><source><italic>International Journal of Oncology</italic></source><year>2006</year><volume>29</volume><issue>1</issue><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="other">2-s2.0-33751113439</pub-id><pub-id pub-id-type="pmid">16773196</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murase</surname><given-names>H.</given-names></name><name><surname>Inokuchi</surname><given-names>M.</given-names></name><name><surname>Takagi</surname><given-names>Y.</given-names></name><name><surname>Kato</surname><given-names>K.</given-names></name><name><surname>Kojima</surname><given-names>K.</given-names></name><name><surname>Sugihara</surname><given-names>K.</given-names></name></person-group><article-title>Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer</article-title><source><italic>Molecular and Clinical Oncology</italic></source><year>2014</year><volume>2</volume><issue>4</issue><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">24940486</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="other"><comment>Dovitinib for Gastric Cancer With FGFR2 Amplification, NCT01719549, 2014, <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01719549?term=fgf+gastric&#x00026;rank=1">http://www.clinicaltrials.gov/ct2/show/NCT01719549?term=fgf+gastric&#x00026;rank=1</ext-link></comment></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fresno Vara</surname><given-names>J. A.</given-names></name><name><surname>Casado</surname><given-names>E.</given-names></name><name><surname>de Castro</surname><given-names>J.</given-names></name><name><surname>Cejas</surname><given-names>P.</given-names></name><name><surname>Belda-Iniesta</surname><given-names>C.</given-names></name><name><surname>Gonz&#x000e1;lez-Bar&#x000f3;n</surname><given-names>M.</given-names></name></person-group><article-title>PI3K/Akt signalling pathway and cancer</article-title><source><italic>Cancer Treatment Reviews</italic></source><year>2004</year><volume>30</volume><issue>2</issue><fpage>193</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2003.07.007</pub-id><pub-id pub-id-type="pmid">15023437</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>B. D.</given-names></name><name><surname>Cantley</surname><given-names>L. C.</given-names></name></person-group><article-title>AKT/PKB signaling: navigating downstream</article-title><source><italic>Cell</italic></source><year>2007</year><volume>129</volume><issue>7</issue><fpage>1261</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id><pub-id pub-id-type="other">2-s2.0-34250788809</pub-id><pub-id pub-id-type="pmid">17604717</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fingar</surname><given-names>D. C.</given-names></name><name><surname>Richardson</surname><given-names>C. J.</given-names></name><name><surname>Tee</surname><given-names>A. R.</given-names></name><name><surname>Cheatham</surname><given-names>L.</given-names></name><name><surname>Tsou</surname><given-names>C.</given-names></name><name><surname>Blenis</surname><given-names>J.</given-names></name></person-group><article-title>mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>2004</year><volume>24</volume><issue>1</issue><fpage>200</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1128/mcb.24.1.200-216.2004</pub-id><pub-id pub-id-type="other">2-s2.0-0345732640</pub-id><pub-id pub-id-type="pmid">14673156</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murayama</surname><given-names>T.</given-names></name><name><surname>Inokuchi</surname><given-names>M.</given-names></name><name><surname>Takagi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Relation between outcomes and localisation of p-mTOR expression in gastric cancer</article-title><source><italic>British Journal of Cancer</italic></source><year>2009</year><volume>100</volume><issue>5</issue><fpage>782</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604915</pub-id><pub-id pub-id-type="other">2-s2.0-61749085803</pub-id><pub-id pub-id-type="pmid">19223902</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velho</surname><given-names>S.</given-names></name><name><surname>Oliveira</surname><given-names>C.</given-names></name><name><surname>Ferreira</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The prevalence of PIK3CA mutations in gastric and colon cancer</article-title><source><italic>European Journal of Cancer</italic></source><year>2005</year><volume>41</volume><issue>11</issue><fpage>1649</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2005.04.022</pub-id><pub-id pub-id-type="other">2-s2.0-22144452507</pub-id><pub-id pub-id-type="pmid">15994075</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukawa</surname><given-names>Y.</given-names></name><name><surname>Yamamoto</surname><given-names>H.</given-names></name><name><surname>Nosho</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2012</year><volume>18</volume><issue>45</issue><fpage>6577</fpage><lpage>6586</lpage><pub-id pub-id-type="doi">10.3748/wjg.v18.i45.6577</pub-id><pub-id pub-id-type="other">2-s2.0-84873885753</pub-id><pub-id pub-id-type="pmid">23236232</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Chang</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>X.</given-names></name></person-group><article-title>Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma</article-title><source><italic>Oncology Letters</italic></source><year>2012</year><volume>4</volume><issue>6</issue><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.3892/ol.2012.930</pub-id><pub-id pub-id-type="other">2-s2.0-84867253682</pub-id><pub-id pub-id-type="pmid">23205120</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="other"><comment>PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer, NCT01613950, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01613950">http://clinicaltrials.gov/show/NCT01613950</ext-link></comment></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>A.</given-names></name><name><surname>Ajani</surname><given-names>J. A.</given-names></name><name><surname>Bai</surname><given-names>Y.-X.</given-names></name><etal/></person-group><article-title>Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2013</year><volume>31</volume><issue>31</issue><fpage>3935</fpage><lpage>3943</lpage><pub-id pub-id-type="doi">10.1200/jco.2012.48.3552</pub-id><pub-id pub-id-type="other">2-s2.0-84891371392</pub-id><pub-id pub-id-type="pmid">24043745</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="other"><comment>RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer, NCT01049620, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01049620?term=pi3k+gastric&#x00026;rank=3">http://clinicaltrials.gov/ct2/show/NCT01049620?term=pi3k+gastric&#x00026;rank=3</ext-link></comment></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="other"><comment>A Randomized, Double Blind Study Evaluating Paclitaxel with and without RAD001 in Patients with Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111), NCT01248403, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01248403">http://clinicaltrials.gov/show/NCT01248403</ext-link></comment></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="other"><comment>PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma&#x02014;A 1st Pilot Metastatic Trial of Biologics Beyond Progression, NCT02213289, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02213289">http://clinicaltrials.gov/show/NCT02213289</ext-link></comment></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(a) Molecular classification of gastric adenocarcinomas. Primary gastric adenocarcinomas (<italic>n</italic> = 295) were analyzed in the TCGA project and found to have four main subtypes: CIN (chromosomal instability) 49.8%, GS (genomically stable) 19.6%, MSI (microsatellite instability) 21.7%, and EBV (Epstein-Barr virus), positive 8.8%. Adapted from data in TCGA [<xref rid="B18" ref-type="bibr">18</xref>]. (b) Characteristics of molecular subtypes of gastric cancer. Adapted from data in TCGA [<xref rid="B18" ref-type="bibr">18</xref>]. The key features of each molecular subtype are listed adjacent to the representation of subtype.</p></caption><graphic xlink:href="GRP2015-896560.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Current and recently completed phase III trials in gastric and gastroesophageal junction cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Agent</th><th align="center" rowspan="1" colspan="1">Clinical trial</th><th align="left" rowspan="1" colspan="1">Randomization</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">NCT identifier</th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1">HER2 inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">Pertuzumab</td><td align="center" rowspan="1" colspan="1">JACOB</td><td align="left" rowspan="1" colspan="1">Pertuzumab in combination with Herceptin and chemotherapy</td><td align="center" rowspan="1" colspan="1">780</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01774786">NCT01774786</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">T-DM1</td><td align="center" rowspan="1" colspan="1">GATSBY</td><td align="left" rowspan="1" colspan="1">T-DM1 with or without taxane.</td><td align="center" rowspan="1" colspan="1">412</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01641939">NCT01641939</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Trastuzumab</td><td align="center" rowspan="1" colspan="1">HELOISE</td><td align="left" rowspan="1" colspan="1">XP-T (standard versus high-dose)</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01450696">NCT01450696</ext-link>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">MET pathway inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">Rilotumumab</td><td align="center" rowspan="1" colspan="1">RILOMET-2</td><td align="left" rowspan="1" colspan="1">XP with or without rilotumumab</td><td align="center" rowspan="1" colspan="1">450</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02137343">NCT02137343</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Rilotumumab</td><td align="center" rowspan="1" colspan="1">RILOMET-1</td><td align="left" rowspan="1" colspan="1">ECX with or without rilotumumab</td><td align="center" rowspan="1" colspan="1">600</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01697072">NCT01697072</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Onartuzumab</td><td align="center" rowspan="1" colspan="1">METGASTRIC</td><td align="left" rowspan="1" colspan="1">FOLFOX with or without onartuzumab</td><td align="center" rowspan="1" colspan="1">800</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01662869">NCT01662869</ext-link>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">Cancer stemness inhibitor</td></tr><tr><td align="left" rowspan="1" colspan="1">BBI608</td><td align="center" rowspan="1" colspan="1">BRIGHTER</td><td align="left" rowspan="1" colspan="1">Paclitaxel with or without BBI608</td><td align="center" rowspan="1" colspan="1">680</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02178956">NCT02178956</ext-link>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">EGFR inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="center" rowspan="1" colspan="1">REAL-3</td><td align="left" rowspan="1" colspan="1">EOX with or without panitumumab</td><td align="center" rowspan="1" colspan="1">574</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00824785">NCT00824785</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cetuximab</td><td align="center" rowspan="1" colspan="1">EXPAND</td><td align="left" rowspan="1" colspan="1">XP with or without cetuximab</td><td align="center" rowspan="1" colspan="1">904</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00678535">NCT00678535</ext-link>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">Angiogenesis inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramucirumab</td><td align="center" rowspan="1" colspan="1">REGARD</td><td align="left" rowspan="1" colspan="1">Ramucirumab versus BSC</td><td align="center" rowspan="1" colspan="1">355</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00917384">NCT00917384</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramucirumab</td><td align="center" rowspan="1" colspan="1">RAINBOW</td><td align="left" rowspan="1" colspan="1">Paclitaxel with or without ramucirumab</td><td align="center" rowspan="1" colspan="1">665</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01170663">NCT01170663</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Regorafenib</td><td align="center" rowspan="1" colspan="1">INTEGRATE</td><td align="left" rowspan="1" colspan="1">Regorafenib versus BSC</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000239864">Actrn12612000239864</ext-link>
</td></tr></tbody></table><table-wrap-foot><fn><p>T-DM1: trastuzumab emtansine; XP: cisplatin, capecitabine; XP-T: cisplatin, capecitabine; T: trastuzumab; ECX: epirubicin, cisplatin, and capecitabine; FOLFOX: 5FU, folinic acid, and oxaliplatin; EOX: epirubicin, oxaliplatin, and capecitabine; BSC: best supportive care. </p></fn></table-wrap-foot></table-wrap></floats-group></article>